珠江角有全国最软的软土,具有高含水率(30%~130%)、高压缩性(1.1~4.2)、低承载力(一般为35~60 k Pa)和深厚等特点,另外还有低渗透性、结构性、流变性、欠固结特性等特点。这些软土特性导致该地区进行基坑设计和施工难度大、造价高和工...珠江角有全国最软的软土,具有高含水率(30%~130%)、高压缩性(1.1~4.2)、低承载力(一般为35~60 k Pa)和深厚等特点,另外还有低渗透性、结构性、流变性、欠固结特性等特点。这些软土特性导致该地区进行基坑设计和施工难度大、造价高和工程事故常有发生的,尤其对于开挖在3~6 m范围内的浅基坑(一层地下室),由于开挖较浅容易被设计、施工和管理单位忽视,使得常发生失稳和局部滑移事故。针对深厚软土浅基坑的特殊性和工程实践中发现的问题,探讨了深厚软土浅基坑支护若干问题:1软土浅基坑常用支护形式及合理支护方案问题;2软土浅基坑失稳破坏模式分析;3软土浅基坑失稳破原因分析;4软土浅基坑被动区加固效果分析;5分析了具体失稳破坏浅基坑工程事故。以上若干问题的分析和探讨为设计浅基坑提供技术支撑,本文成果可为优化设计和施工提供了有益的参考,为类似工程提供借鉴。展开更多
Background Heart failure （HF） is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiogra...Background Heart failure （HF） is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiography and biochemical tests. Galectin-3, a rela-tively new biomarker in HF, was approved by the US Food and Drug Administration in 2010 as a marker in the stratification of risk for HF. We assessed galectin-3 as a biomarker for HF diagnosis in patients with preserved ejection fraction （pEF） and compared its performance with that of B-type natriuretic peptide （BNP）. Methods Thirty-five pEF patients with HF （HFpEF group） and 43 pEF patients without HF （control group） were enrolled. Plasma levels of galectin-3 and BNP in HFpEF and control subjects were determined. Sensitivity, specificity, pre dictive values, and accuracy of galectin-3 and BNP as markers for HF diagnosis were calculated and compared. Results Levels of galec- tin-3 and BNP were 23.09 ±6.97 ng/mL and 270.46 ± 330.41 pg/mL in the HFpEF group, and 16.74 ± 2.75 ng/mL and 59.94 ± 29.93 pg/mL in the control group, respectively. Differences in levels of galectin-3 and BNP between the two groups were significant （P 〈 0.01）. As a bio- marker for HF diagnosis in study subjects, galectin-3 showed sensitivity and specificity of 94.3% and 65.1%, respectively, at a cutoff value of 17.8 ug/mL. BNP showed sensitivity and specificity of 77.1% and 90.7%, respectively, at a cutoff value of 100 pg/mL. Galectin-3 was a significantly more sensitive （P 〈 0.05） but less specific （P 〈 0.01） biomarker compared with BNP. Differences in positive predictive value, negative predictive value, and accuracy between galectin-3 and BNP markers were not significant （P 〉 0.05）. Areas under the receiver operating characteristic curve （95% confidence interval） were 0.891 （0.808-0.974） and 0.896 （0.809-0.984） for galectin-3 and BNP, respec- tively, with no significant difference between the two values （P 〉 0.05）. Co展开更多
文摘珠江角有全国最软的软土,具有高含水率(30%~130%)、高压缩性(1.1~4.2)、低承载力(一般为35~60 k Pa)和深厚等特点,另外还有低渗透性、结构性、流变性、欠固结特性等特点。这些软土特性导致该地区进行基坑设计和施工难度大、造价高和工程事故常有发生的,尤其对于开挖在3~6 m范围内的浅基坑(一层地下室),由于开挖较浅容易被设计、施工和管理单位忽视,使得常发生失稳和局部滑移事故。针对深厚软土浅基坑的特殊性和工程实践中发现的问题,探讨了深厚软土浅基坑支护若干问题:1软土浅基坑常用支护形式及合理支护方案问题;2软土浅基坑失稳破坏模式分析;3软土浅基坑失稳破原因分析;4软土浅基坑被动区加固效果分析;5分析了具体失稳破坏浅基坑工程事故。以上若干问题的分析和探讨为设计浅基坑提供技术支撑,本文成果可为优化设计和施工提供了有益的参考,为类似工程提供借鉴。
文摘Background Heart failure （HF） is a common disease with complex pathophysiological causes. The diagnosis of HF commonly relies on comprehensive analyses of medical history and symptoms, and results from echocardiography and biochemical tests. Galectin-3, a rela-tively new biomarker in HF, was approved by the US Food and Drug Administration in 2010 as a marker in the stratification of risk for HF. We assessed galectin-3 as a biomarker for HF diagnosis in patients with preserved ejection fraction （pEF） and compared its performance with that of B-type natriuretic peptide （BNP）. Methods Thirty-five pEF patients with HF （HFpEF group） and 43 pEF patients without HF （control group） were enrolled. Plasma levels of galectin-3 and BNP in HFpEF and control subjects were determined. Sensitivity, specificity, pre dictive values, and accuracy of galectin-3 and BNP as markers for HF diagnosis were calculated and compared. Results Levels of galec- tin-3 and BNP were 23.09 ±6.97 ng/mL and 270.46 ± 330.41 pg/mL in the HFpEF group, and 16.74 ± 2.75 ng/mL and 59.94 ± 29.93 pg/mL in the control group, respectively. Differences in levels of galectin-3 and BNP between the two groups were significant （P 〈 0.01）. As a bio- marker for HF diagnosis in study subjects, galectin-3 showed sensitivity and specificity of 94.3% and 65.1%, respectively, at a cutoff value of 17.8 ug/mL. BNP showed sensitivity and specificity of 77.1% and 90.7%, respectively, at a cutoff value of 100 pg/mL. Galectin-3 was a significantly more sensitive （P 〈 0.05） but less specific （P 〈 0.01） biomarker compared with BNP. Differences in positive predictive value, negative predictive value, and accuracy between galectin-3 and BNP markers were not significant （P 〉 0.05）. Areas under the receiver operating characteristic curve （95% confidence interval） were 0.891 （0.808-0.974） and 0.896 （0.809-0.984） for galectin-3 and BNP, respec- tively, with no significant difference between the two values （P 〉 0.05）. Co
